NCT05565417 - Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 28, 2022

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions

Non Small Cell Lung CancerHead and Neck Squamous Cell CarcinomaTriple Negative Breast CancerCutaneous Squamous Cell CarcinomaHormone Receptor Positive Breast CarcinomaSmall Bowel CancerEsophageal CancerColorectal CancerDiffuse Large B Cell LymphomaHodgkin LymphomaBurkitt LymphomaFollicular Lymphoma

Interventions

DRUG

IMT-009

Participants will receive an IV infusion of IMT-009 on Day 1 during each 21-day cycle.

COMBINATION_PRODUCT

Fruquintinib

Fruquintinib will be administered according to the FDA-approved United States Prescribing Information (USPI).

Trial Locations (9)

22031

Site 9112, Fairfax

32827

Site 4100, Orlando

34232

Site 4060, Sarasota

37203

Site 3000, Nashville

73104

Site 4500, Oklahoma City

78705

Site 9384, Austin

80218

Site 5000, Denver

85711

Site 9618, Tucson

97239

Site 9280, Portland